NCT03706326

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The First Affiliated Hospital of Guangdong Pharmaceutical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.

Detailed description

This is a combined phase 1 and 2 clinical study. The aim of the study is to assess the safety and efficacy of the immunotherapies using anti- MUC1 CAR T cells alone, anti- MUC1 CAR T combining PD-1 knockout engineered T cells, and PD-1 knockout engineered T cell only in the treatment of patients with advanced esophageal cancer. The treatment outcomes from each group will be compared.

Conditions

• Advanced Esophageal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Anti-MUC1 CAR-T cells	Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
BIOLOGICAL	PD-1 knockout Engineered T cells	Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
COMBINATION_PRODUCT	CAR-T combined with PD-1 Knockout T cells	Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients

Timeline

• Start date: 2018-09-28
• Primary completion: 2021-09-28
• Completion: 2021-09-28
• First posted: 2018-10-16
• Last updated: 2018-10-16

Locations

2 sites across 1 country: China